Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 8/20 | 0.46 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.44 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.44 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4877851 | 0.91 | MAPK14 (0.49) | MAPK14MAPK13MAPK12MAPK11HTT | |
| SCHEMBL4877819 | 0.81 | MAPK14 (0.49) | MAPK14MAPK13MAPK12MAPK11HTT | |
| SCHEMBL2036353 | 0.81 | CES2 (0.46) | MAPK14MAPK13MAPK12MAPK11HTT | |
| SCHEMBL4924074 | 0.81 | MAPK14 (0.41) | MAPK14MAPK13MAPK12MAPK11HTT | |
| SCHEMBL4877345 | 0.80 | MAPK14 (0.42) | MAPK14MAPK13MAPK12MAPK11HTT | |
| SCHEMBL4876877 | 0.78 | MAPK14 (0.42) | MAPK14MAPK13MAPK12MAPK11HTT | |
| SCHEMBL2027920 | 0.77 | CES2 (0.35) | MAPK14MAPK13MAPK12MAPK11HTT | |
| SCHEMBL2027918 | 0.77 | CES2 (0.35) | MAPK14MAPK13MAPK12MAPK11HTT | |
| SCHEMBL1504738 | 0.76 | ALDH1A1 (0.44) | MAPK14HTTKMT2AALDH1A1LMNA | |
| SCHEMBL4879034 | 0.76 | MAPK14 (0.39) | MAPK14MAPK13MAPK12MAPK11HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080081825-A1 | Nitrogen-Containing Heterocyclic Compounds and Medicinal Use Thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-04-03 | — | — | US | disclosed |
| EP-1741702-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081825-A1 | Nitrogen-Containing Heterocyclic Compounds and Medicinal Use Thereof | MAPK1, NOS1, NOS2 | MAPK14 13/4885MAPK13 12/4885MAPK12 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.